<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606423</url>
  </required_header>
  <id_info>
    <org_study_id>11165</org_study_id>
    <secondary_id>I1R-FW-GLBC</secondary_id>
    <nct_id>NCT01606423</nct_id>
  </id_info>
  <brief_title>The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants</brief_title>
  <official_title>The Effect of LY2409021 on Blood Glucose Concentrations During Hyperglucagonaemia in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to measure the effect that various doses of LY2409021 have on blood sugar
      levels and on the amount of glucose released by the liver, when glucagon is given to increase
      these. Each participant may receive up to 2 single doses of LY2409021 in 2 different study
      periods, with a minimum 13-day washout between dosing periods. This study is approximately 9
      weeks long, not including screening. A screening appointment is required within 6 weeks prior
      to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum glucose response during a 3-hour glucagon infusion</measure>
    <time_frame>During a 3-hour glucagon infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total glucose released from the liver during a 3-hour glucagon infusion</measure>
    <time_frame>During a 3-hour glucagon infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum glucose release from the liver during a 3-hour glucagon infusion</measure>
    <time_frame>During a 3-hour glucagon infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22.5 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>22.5 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg LY2409021 administered once, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg LY2409021 administered once, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally, single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2409021</intervention_name>
    <description>Administered orally, single dose</description>
    <arm_group_label>10 mg LY2409021</arm_group_label>
    <arm_group_label>22.5 mg LY2409021</arm_group_label>
    <arm_group_label>60 mg LY2409021</arm_group_label>
    <arm_group_label>200 mg LY2409021</arm_group_label>
    <arm_group_label>500 mg LY2409021</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a healthy male

          -  Have a screening body mass index (BMI) of 18.5 to 29.9 kg/m^2 inclusive

          -  Have a fasting blood glucose between 3.0-6.0 millimoles/liter (mmol/L) (inclusive) at
             screening

        Exclusion Criteria:

          -  Are allergic to LY2409021, insulin, glucagon, somatostatin, or similar drugs

          -  Have a regular alcohol intake greater than 21 units/week, or are unwilling to stop
             alcohol as required by the study restrictions (1 unit = 360 mL of beer, or 150 mL of
             wine, or 45 mL of spirits)

          -  Are currently smokers or have used tobacco products on a regular basis in the 6 months
             prior to screening

          -  Have received any medication known to affect glucose metabolism in the 1 month before
             the study

          -  Have a significant blood disorder and/or donated blood (450 mL or more) in the last 3
             months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

